MW08

MW08 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Moonwalk Biosciences for the treatment of obesity. The drug is designed to modulate adipose endocrine function, a critical component in metabolic regulation and energy homeostasis. Moonwalk Biosciences utilizes a proprietary epigenetic engineering platform to identify and target specific genomic regions, aiming to restore healthy cell states by modifying the epigenetic landscape without altering the underlying DNA sequence. MW08 is part of a broader cardiometabolic pipeline that includes other candidates targeting lipolysis, thermogenesis, and adipogenesis.